Brodalumab psoriasis results published, development plans continue

Brodalumab met all primary endpoints against its first-in-class rival, ustekinumab, and against placebo in two phase III trials of more than 3,700 patients with moderate to severe plaque psoriasis, investigators reported in the New England Journal of Medicine. The results of the two studies, <a...
Source: Skin and Allergy News - Category: Dermatology Source Type: news